MDxHealth SA (NASDAQ:MDXH) Sees Significant Decrease in Short Interest

MDxHealth SA (NASDAQ:MDXH) was the recipient of a significant drop in short interest in the month of February. As of February 15th, there was short interest totalling 13,300 shares, a drop of 22.7% from the January 31st total of 17,200 shares. Based on an average daily volume of 121,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.1% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

Separately, Piper Sandler cut their target price on shares of MDxHealth from $8.00 to $6.00 and set an “overweight” rating for the company in a research report on Thursday, November 7th.

Hedge Funds Weigh In On MDxHealth

A number of large investors have recently modified their holdings of MDXH. AWM Investment Company Inc. lifted its position in MDxHealth by 11.1% during the fourth quarter. AWM Investment Company Inc. now owns 4,721,290 shares of the company’s stock valued at $11,189,000 after purchasing an additional 471,290 shares during the last quarter. MVM Partners LLC lifted its position in MDxHealth by 3.3% during the third quarter. MVM Partners LLC now owns 4,700,457 shares of the company’s stock valued at $9,706,000 after purchasing an additional 150,000 shares during the last quarter. Samjo Management LLC lifted its position in MDxHealth by 130.9% during the fourth quarter. Samjo Management LLC now owns 1,824,312 shares of the company’s stock valued at $4,324,000 after purchasing an additional 1,034,312 shares during the last quarter. Perkins Capital Management Inc. lifted its position in MDxHealth by 31.6% during the fourth quarter. Perkins Capital Management Inc. now owns 983,475 shares of the company’s stock valued at $2,331,000 after purchasing an additional 236,100 shares during the last quarter. Finally, Northern Trust Corp bought a new stake in MDxHealth during the fourth quarter valued at approximately $1,033,000.

MDxHealth Price Performance

MDXH stock opened at $1.71 on Tuesday. The firm has a 50 day moving average of $2.00 and a 200-day moving average of $2.18. The company has a current ratio of 1.54, a quick ratio of 1.45 and a debt-to-equity ratio of 3.14. MDxHealth has a 12 month low of $1.55 and a 12 month high of $3.85. The firm has a market capitalization of $80.86 million, a P/E ratio of -1.13 and a beta of 1.34.

MDxHealth (NASDAQ:MDXH) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.07. MDxHealth had a negative net margin of 49.52% and a negative return on equity of 1,077.84%. The company had revenue of $24.74 million during the quarter, compared to analyst estimates of $22.67 million. As a group, sell-side analysts predict that MDxHealth will post -1.15 earnings per share for the current fiscal year.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.